Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 10/27/22 → 9/13/24 |
Funding
- Novartis (domestic): $26,275.00
Victorian-2 Prevent: A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing The Impact of Inclisiran On Major Adverse Cardiovascular Events In Participants With Established Cardiovascular Disease
- Kotter, John (PI)